How Long Does CBD Stay in Your System?

CBD does not run on one clearance clock. After a single use, one laboratory might stop measuring CBD in one specimen while a more sensitive assay could still find a metabolite in another. Repeated use can produce a different pattern. And a workplace cannabis test may not be looking for CBD at all.

That is why a responsible answer starts by asking what you mean by "stay in your system." Are you asking when an effect ends, when the amount in plasma falls by half, how long a research laboratory can measure CBD, or whether a THC-focused test could be positive? Those questions overlap, but they are not interchangeable.

This guide explains the evidence without giving a personalized countdown. If your immediate concern is an employment, athletic, legal or clinical test, read the dedicated CBD and drug testing guide and check the rules of the program that will actually test you.

The four different clocks

A negative result for one analyte does not prove that every CBD-related compound is absent. A measurable CBD metabolite also does not automatically mean a standard workplace cannabis screen will report a positive. The test's target and cutoff matter.

What CBD half-life can tell you

Half-life is the time required for a measured concentration to fall by half during a defined phase of elimination. It is useful for comparing pharmacokinetic profiles. It is not a timer that announces when a substance is completely gone, when an effect ends or when every possible test becomes negative.

The current FDA prescribing information for Epidiolex, a purified prescription CBD oral solution, reports a plasma half-life of 56 to 61 hours after healthy volunteers received it twice daily for seven days. That is a reliable statement about that formulation and regimen. It is not evidence that a consumer tincture remains in every person's body for the same period. The studied prescription doses were also far higher than many consumer servings.

A phase 1 trial of the same highly purified formulation illustrates another complication. Researchers reported an approximately 60-hour terminal half-life after repeated high doses, while effective half-life estimates were 10 to 17 hours. Terminal half-life describes the slow final phase captured by the model. Effective half-life is more closely tied to accumulation during repeated dosing. Both can be valid, but they answer different technical questions. The trial was funded by the product developer, GW Research Ltd, and studied healthy volunteers under controlled conditions.

A systematic review of human CBD pharmacokinetics found reported half-lives ranging from roughly one hour to five days. The widest estimates came from studies that differed in route, dose, repeated versus single use, formulation and sampling design. The authors emphasized that the evidence was sparse and inconsistent. The range describes a research literature, not the likely window for one reader.

Route, formulation, dose and frequency change the picture

CBD exposure is not determined by milligrams alone. An oral oil, capsule, prescription solution, vapor and topical product do not create interchangeable concentration curves. Even two oral formulations can produce different measured concentrations. Food can also change exposure for some oral formulations. These variables are reasons for uncertainty, not instructions to change how you use a product.

In a controlled study of 18 healthy adults, researchers administered 100 mg of CBD by vaporization or in three oral formulations and collected urine for 58 hours. Average peak urinary CBD concentration and time to that peak differed by route, and the three oral formulations produced substantially different peak concentrations. A 58-hour research collection can describe what happened in that protocol. It cannot establish the last possible detection time after lower servings, long-term use or a different assay.

Repeated use adds another layer because concentration from one serving may not have completed its decline before the next serving. Liver function, interacting medicines and individual physiology may also change exposure. The FDA warns that CBD can interact with medicines and can carry risks that are not obvious to the user. For practical safety information, see CBD side effects and interactions and discuss use with a qualified healthcare professional when medicines or liver concerns are involved.

How long is CBD detectable in blood, urine, saliva or hair?

There is no validated specimen-by-specimen chart that covers the full range of consumer CBD products and patterns of use. A detection window must name the specimen, the exact target compound or metabolite, the analytical method and the cutoff. Without those details, a number of days is not a reproducible scientific claim.

Blood or plasma pharmacokinetic studies often measure CBD itself and selected metabolites at scheduled times. Urine studies may measure CBD, 7-hydroxy-CBD, 7-carboxy-CBD or THC-related compounds. The reviewed evidence does not establish a consumer detection timeline for CBD in oral fluid or hair. Specimen, analyte, assay and cutoff must be known before a result can be interpreted.

This is also why the duration of a felt effect cannot substitute for laboratory evidence. You may notice nothing while a sensitive research assay still measures a compound. Conversely, a symptom or sensation is not proof that CBD remains at a particular concentration.

What workplace cannabis tests usually look for

Federal workplace cannabis testing does not use CBD as its marijuana target. The current SAMHSA Medical Review Officer guidance lists delta-9 THC carboxy metabolite for urine, with a 50 ng/mL initial cutoff and a 15 ng/mL confirmation cutoff. For federal oral-fluid testing, the target is delta-9 THC, with 4 ng/mL initial and 2 ng/mL confirmation cutoffs. Those federal rules do not automatically govern every private employer, court, clinic, sports body or state program.

The distinction matters because purified CBD and a CBD-dominant product that contains THC are not the same exposure. In the 18-person controlled study, researchers found no evidence that administered pure CBD converted to delta-8 or delta-9 THC. But after participants vaporized CBD-dominant cannabis containing 100 mg CBD and 3.7 mg delta-9 THC, 3 of 18 produced urine samples at or above the 15 ng/mL confirmation threshold. Two of those samples also screened positive at the 50 ng/mL cutoff.

A newer controlled repeated-exposure study assigned 60 healthy adults to 100 mg CBD with zero or low amounts of delta-9 THC. During 14 days of twice-daily use, at least one participant in every condition containing any THC produced a positive urine test. The paper reports positives after the one-week washout but is internally inconsistent about the count: its abstract says two, while the Results narrative says only one. One specimen in the CBD-only group was also positive, but the study did not establish why and that result does not show that CBD converted to THC. The small groups, fixed research formulation and reporting inconsistency prevent a personal prediction. The study also involved academic, federal, testing-laboratory and Charlotte's Web-affiliated authors, which is relevant when weighing the evidence.

A safer decision guide when a test matters

1. 1Identify the actual program. Ask which specimen, panel, analytes and policy apply. Federal guidance is not a universal private-employer rule.
2. 2Do not convert a CBD half-life into a promised negative date. The relevant risk may be THC in the product, not direct CBD detection.
3. 3Review the batch-specific certificate of analysis, including the laboratory, lot match, delta-9 THC result, reporting units and limit of quantification. Use the [COA reading guide](/blog/how-to-read-a-coa) if those fields are unfamiliar.
4. 4Treat a COA as evidence, not a guarantee. Sampling, batch variation, labeling error and the testing program's own method can still matter.
5. 5If consequences are material, contact the program, employer policy owner or Medical Review Officer before making assumptions. Ask how reported positives, confirmation and disclosures are handled.
6. 6Do not treat detox products, excessive water or other attempts to manipulate a specimen as a clearance calculation. The reviewed evidence did not establish a method that makes a sample negative by a chosen time.

Product quality is not an abstract concern. The FDA says many nonprescription CBD products have not been evaluated for quality and has investigated inaccurate cannabinoid content and possible THC contamination. In a 2017 laboratory analysis of 84 online CBD extracts, only 26 were within 10% of the labeled CBD amount and THC was detected in 18 samples. That historical sample does not describe every current product or any specific Planntz lot, but it shows why a category name alone cannot settle testing risk.

What you can conclude, and what you cannot

You can conclude that CBD pharmacokinetics vary, repeated use and formulation matter, and a THC-containing product creates a different testing question from purified CBD. You can also conclude that federal workplace testing uses defined THC-related analytes and cutoffs.

You cannot use those facts to calculate the day when a particular person will test negative. You cannot assume that a product labeled broad-spectrum or isolate contains no measurable THC. And you cannot infer elimination from how you feel. A careful answer sometimes ends with uncertainty because the requested personal prediction has not been studied.